New hope for blood cancer patients: major trial tests promising drug duo

NCT ID NCT07277231

Summary

This study aims to see if a new combination of drugs (sonrotoclax plus zanubrutinib) works better and is safer than a current standard combination (venetoclax plus acalabrutinib) for people newly diagnosed with chronic lymphocytic leukemia (CLL). It will involve about 500 adults who have not yet received any treatment for their CLL. The main goals are to see which treatment keeps the cancer from progressing longer and which leads to deeper remission with no detectable cancer cells.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Auckland City Hospital

    RECRUITING

    Auckland, 1023, New Zealand

  • Cabrini Hospital Malvern

    RECRUITING

    Malvern East, Victoria, VIC 3144, Australia

  • Genesiscare North Shore

    RECRUITING

    St Leonards, New South Wales, NSW 2065, Australia

  • North Shore Hospital

    RECRUITING

    Auckland, 0622, New Zealand

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • The Alfred Hospital

    RECRUITING

    Melbourne, Victoria, VIC 3004, Australia

  • The Catholic University of Korea, Seoul St Marys Hospital

    RECRUITING

    SeochoGu, Seoul Teugbyeolsi, 06591, South Korea

Conditions

Explore the condition pages connected to this study.